AstraZeneca hands José Baselga a 'dream job' in shake-up

7 January 2019

Some four months after resigning from his role as physician-in-chief at Memorial Sloan Kettering Cancer Center (MSK) and stepping down from the board of US pharma major Bristol-Myers Squibb (NYSE: BMY), José Baselga (pictured above) has been given another chance.

Dr Baselga stood down after a scandal surrounding his failure to disclose payments he received in connection with research articles, but it evidently is not an issue of major concern to AstraZeneca (LSE: AZN).

The Anglo-Swedish pharma major has given him a major role as part of organizational changes that were announced on Monday.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK